-
Januvia, Onglyza, Other Diabetes Drugs In DPP-4 Inhibitor Class Significantly Increase Risk Of Crohn’s Disease (CD)
But Same Medical Study Finds That DPP-4 Inhibitors Do Not Increase Risk Of Inflammatory Bowel Disease (IBD) (Posted by Tom Lamb at DrugInjuryWatch.com) Back in March 2018 we wrote this report, “Januvia,…
-
Uloric Recall, “Black-Box Warning”, And Limited Use Discussed By FDA Advisory Committees In January 2019
Despite Drug Safety Problem Of Cardiovascular Mortality, Benefits Might Be Seen To Outweigh Risks For Select Gout Patients (Posted by Tom Lamb at DrugInjuryWatch.com) Uloric (febuxostat) was approved by the FDA in…
-
There Is A Warning About Increased Risk Of Lower Limb Amputations For Invokana And Invokamet (Only)
Going Into 2019 The Issue Of These Amputations Being An SGLT2 Inhibitors Drug Class Side Effect Remains Open To Debate (Posted by Tom Lamb at DrugInjuryWatch.com) A year-and-a-half ago we wrote this…
-
Breast Implants Recall: Allergan Textured Products In Europe Removed From Market December 2018
Regulatory Action In France Due To Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Cases (Posted by Tom Lamb at DrugInjuryWatch.com) There have been more than 600 cases of Breast Implant-Associated Anaplastic Large…
-
Diabetes Drugs In DPP-4 Inhibitor Class Associated With Almost Two-Times Increased Risk Of Cholangiocarcinoma
Medical Researchers Finding This Rare But Highly Fatal Cancer Call For More Investigation Into New Possible Drug Side Effect (Posted by Tom Lamb at DrugInjuryWatch.com) A recent medical study shows that the…
-
Lemtrada: Warnings About Strokes And Arterial Dissections / Blood Vessel Lining Damage Added To Drug Label
Symptoms Developed Within Just One Day Of Lemtrada Injections, And Can Lead To Patient Death Or Permanent Disability Says FDA (Posted by Tom Lamb at DrugInjuryWatch.com) In late November 2018 this FDA…